INTERNATIONAL DESK — The US Food and Drug Administration has granted approval for a novel perioperative immunotherapy regimen developed by AstraZeneca, offering a critical therapeutic alternative for adults diagnosed with muscle-invasive bladder cancer who cannot tolerate or decline cisplatin-based chemotherapy. Announced by the Newsbeat Desk, the authorization covers the application of Imfinzi, known generically as durvalumab, administered in combination with enfortumab vedotin prior to surgery, followed by single-agent Imfinzi post-operatively.
The regulatory decision is underpinned by robust data from the Phase III VOLGA clinical trial, which was featured at the 2026 European Society for Medical Oncology Congress. Trial evaluations established that the combination therapy lowered the combined risk of disease progression, recurrence, failure to undergo surgery, or death by 49 percent compared to surgical intervention alone. Furthermore, the protocol demonstrated a 42 percent decrease in overall mortality risk, with 64 percent of patients remaining event-free at the two-year milestone, contrasted with 45 percent in the comparator arm.
Clinical experts highlighted that muscle-invasive tumors account for roughly one-quarter of all bladder cancer cases, with up to half of these individuals disqualified from standard cisplatin regimens due to compromised renal function or concurrent medical conditions. Historically, such cohorts relied entirely on radical cystectomy, which carries elevated recurrence probabilities. The VOLGA trial findings suggest the regimen may redefine therapeutic benchmarks in curative-intent settings, addressing a long-standing clinical gap for high-risk patients.
Following the domestic authorization, similar regulatory submissions for the therapy are undergoing active evaluation across the European Union, Japan, and other international jurisdictions. This latest decision represents AstraZeneca's third approved indication within the oncology sector over a two-year span. Meanwhile, trial monitoring noted that Grade 3 or 4 adverse events occurred in 64 percent of patients receiving the combination therapy, compared to 44 percent in the control group, aligning with the established safety profiles of the individual components.